Answers are grounded in this paper and cite their sources.
Sarcoid-like granulomatous reactions can mimic metastatic progression on 18F-FDG PET/CT after immune checkpoint inhibitor exposure. We report a 37-year-old woman with triple-negative invasive ductal breast carcinoma and radiologically suspected pulmonary metastases treated with gemcitabine, carboplatin, and pembrolizumab. Increased thoracic nodal uptake and new skeletal foci in March 2025 were interpreted as progression without tissue confirmation, prompting a switch to capecitabine. Subsequent PET/CT demonstrated discordant nodal, pulmonary, and osseous changes. In February 2026, ultrasound-guided supraclavicular lymph-node biopsy demonstrated non-necrotizing granulomatous inflammation without malignancy; cytokeratin AE1/AE3, acid-fast bacilli, and Grocott stains were negative. The findings were consistent with sarcoidosis or sarcoid-like inflammation at the sampled site, but the nature of unsampled lesions and the association with pembrolizumab remained uncertain. Capecitabine was continued under surveillance, while corticosteroids were withheld because of absent symptoms and no demonstrated organ-threatening involvement. August 2026 PET/CT demonstrated fluctuating nodal uptake, stable indeterminate pulmonary nodules, and no new FDG-avid focus suspicious for metastatic disease. At pulmonology follow-up in October 2026, she remained asymptomatic despite reduced DLCO (65% predicted); additional organ assessment was ongoing. This case highlights the importance and limitations of tissue confirmation in interpreting apparent progression after immunotherapy.
No takes yet. Share an insight, caveat, or question.
Wafi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: